Intervention not reported
No condom use at last vaginal sex (3 months) · middle or high school students with need for contraceptive information
The intervention probably leads to lower no condom use at last vaginal sex (3 months) (moderate certainty).
1 finding from 1 review
OR 0.67 [0.47, 0.96]
15 participants
Moderate
Intervention not reported
Vaginal sex without condom in past 3 months (3 months) · middle or high school students with need for contraceptive information
The intervention probably leads to lower vaginal sex without condom in past 3 months (3 months) (moderate certainty).
1 finding from 1 review
OR 0.59 [0.36, 0.95]
15 participants
Moderate
Intervention not reported
No condom use at last vaginal sex: 3 months; 15 months · middle or high school students with need for contraceptive information
1 finding from 1 review
no estimate extracted
15 participants
Moderate
Intervention not reported
Oral contraceptive use during last sex (17 months) · middle or high school students with need for contraceptive information
The intervention probably leads to lower oral contraceptive use during last sex (17 months) (moderate certainty).
1 finding from 1 review
OR 0.57 [0.36, 0.91]
102 participants
Moderate
Mutans streptococci prevalence (presence/absence) · Children and adolescents below 18 years at study start (included studies: children from birth to 15 years), with mixed, permanent or…
It is very uncertain whether chlorhexidine gel (0.12%) changes mutans streptococci prevalence (presence/absence) compared with no treatment (very low certainty).
1 finding from 1 review
Chlorhexidine oral product (one formulation/concentration) vs Another chlorhexidine formulation, concentration or application frequency
Outcome not reported · Children and adolescents below 18 years at study start (included studies: children from birth to 15 years), with mixed, permanent or…
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
0 studies
No studies found
Adverse events · Children and adolescents below 18 years at study start (included studies: children from birth to 15 years), with mixed, permanent or…
1 finding from 1 review
Oral mucositis (severe) · Patients with osteosarcoma (bone cancer) receiving high-dose methotrexate, vincristine and leucovorin
1 finding from 1 review
Oral mucositis (severe). Not estimable - no participants had developed severe oral mucositis by the fourth day after chemotherapy when the data were reported (Zhang 2011, Analysis 4.3, subgroup 3.1); 118 participants…
1 study · 118 participants
GRADE not reported
Adverse events (e.g. ulcers, tooth staining) · Children and adolescents below 18 years at study start (included studies: children from birth to 15 years), with mixed, permanent or…
1 finding from 1 review
Chlorhexidine mouthrinse vs Placebo or no intervention (including routine care)
Outcome not reported · Children and adolescents below 18 years at study start (included studies: children from birth to 15 years), with mixed, permanent or…
The review found no eligible studies for this question.
1 finding from 1 review
Pain, quality of life, patient satisfaction or costs · Children and adolescents below 18 years at study start (included studies: children from birth to 15 years), with mixed, permanent or…
The review found no eligible studies for this question.
1 finding from 1 review
Oral mucositis (any severity) · Patients with osteosarcoma (bone cancer) receiving high-dose methotrexate, vincristine and leucovorin
It is very uncertain whether oral cryotherapy (ice chips, ice-cold water, ice cubes or crushed… changes oral mucositis (any severity) compared with low-dose leucovorin rinse (very low certainty).
1 finding from 1 review
Oral mucositis (moderate to severe) · Patients with osteosarcoma (bone cancer) receiving high-dose methotrexate, vincristine and leucovorin
It is very uncertain whether oral cryotherapy (ice chips, ice-cold water, ice cubes or crushed… changes oral mucositis (moderate to severe) compared with low-dose leucovorin rinse (very low certainty).
1 finding from 1 review
Sudden cardiac death · participants with high risk of sudden cardiac death (primary prevention)
Amiodarone may leads to lower sudden cardiac death compared with placebo or no treatment (low certainty).
1 finding from 1 review
All‐cause mortality · participants with high risk of sudden cardiac death (secondary prevention)
Amiodarone showed no clear difference in all‐cause mortality compared with other antiarrhythmics (low certainty).
1 finding from 1 review
Sudden cardiac death · participants with high risk of sudden cardiac death (secondary prevention)
It is very uncertain whether amiodarone changes sudden cardiac death compared with beta blockers (very low certainty).
1 finding from 1 review
All‐cause mortality · participants with high risk of sudden cardiac death (secondary prevention)
It is very uncertain whether amiodarone changes all‐cause mortality compared with beta blockers (very low certainty).
1 finding from 1 review
Sudden cardiac death · participants with high risk of sudden cardiac death (secondary prevention)
It is very uncertain whether amiodarone changes sudden cardiac death compared with sotalol (very low certainty).
1 finding from 1 review
All‐cause mortality · participants with high risk of sudden cardiac death (secondary prevention)
It is very uncertain whether amiodarone changes all‐cause mortality compared with sotalol (very low certainty).
1 finding from 1 review
All‐cause mortality · participants with high risk of sudden cardiac death (primary prevention)
Amiodarone showed no clear difference in all‐cause mortality compared with placebo or no treatment (low certainty).
1 finding from 1 review